A Phase 2 Multicenter, Open Label, Randomized Study of Two Titration Regimens of Oral CXA-10 in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS)

Site Image

Study Overview

Primary FSGS is a progressive disease that causes the kidneys to scar, to leak protein into the urine and may lead to kidney failure. This study is being done to see whether a new medication, called CXA-10, can reduce the amount of protein in the urine and maintain stable kidney function in patients with primary FSGS. CXA-10 is an investigational medication which means it has not yet been approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary FSGS. The pharmaceutical company sponsoring this study is Complexa, inc.

  • Study Identifier: 831546

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu